ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Published Sep 9, 2025

Lawrenceville, NJ, USA— September 9,  2025—ISPORThe Professional Society for Health Economics and Outcomes Research (HEOR) announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

The Summit features plenary sessions, workshops, and breakout discussions on today’s most pressing topics, each tied to the bigger picture of real-world evidence (RWE) including health equity, HTA, value-based healthcare, generative AI, health policy, drug price negotiations, and beyond.

Sessions include:

Plenary 1: Realizing RWE Potential in Asia Pacific: Opportunities, Challenges, and Progress
Monday 29, September 2025  
This plenary session examines the evolving landscape of real-world evidence across the Asia Pacific region, where adoption varies significantly between countries despite growing interest. 

Speakers Include:

  • Moderator: Fei-Yuan Sharon Hsiao, PhD, College of Medicine, National Taiwan University, Taipei, Taiwan
  • Mahendra Kumar Rai, PhD, EVERSANA, Singapore, Singapore
  • Sallie Pearson, PhD, The University of New South Wales, Sydney, Australia
  • Bor-Sheng Ko, PhD, MD, National Taiwan University Hospital, New Taipei City, Taiwan
  • Boxiong Tang, PhD, MD, TZ Health, Collegeville, PA, United States
  • Yoshiaki Uyama, PhD, Pharmaceuticals & Medical Devices Agency (PMDA), Tokyo, Japan

Plenary 2: Building the Future: Advancing Real-World Evidence in Asia Pacific and Beyond Tuesday 30, September This plenary panel explores the future for RWE in HEOR and addresses questions around HEOR and how to optimize the use of RWE.

Speakers Include:

  • Moderator: Paul Scuffham, PhD, Griffith University, Gold Coast, Australia
  • Bruce Crawford, MA, MPH, Vista Health Japan KK, Tokyo, Japan
  •  Jing Wu, PhD, Tianjin University, Tianjin, China
  • Ji-Hye Byun, PhD, Health Insurance Review & Assessment Service, Wonju , Korea
  • Azuana Ramli, PhD, Ministry of Health, Petaling Jaya, Malaysia

ISPOR is recognized globally as the leading professional society for health economics and outcomes research and for its role in improving healthcare decisions. The Summit draws healthcare stakeholders from the region with an interest in HEOR, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

Additional information on the conference can be found at:
Conference Information | Program | Press | Exhibits & Sponsorship | Registration

###

ABOUT ISPOR
ISPOR—The Professional Society for Health Economics and Outcomes Research
(HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website
 | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram  

 

 

 

 

Related Stories

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×